Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228212 | 0.86 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL1964183 | 0.84 | KDM1A (0.38) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL21162862 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL9893515 | 0.83 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL30277219 | 0.82 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL25148013 | 0.80 | CHRM2 (0.45) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL20973202 | 0.79 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL21274860 | 0.79 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL27228213 | 0.77 | CHRM2 (0.42) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL16468545 | 0.77 | CTSK (0.42) | CHRM2CHRM1CHRM3EPHX2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173439-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | TDK CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-2743271-B1 | PIM KINASE INHIBITORS AND PREPARATION METHOD AND USE IN MEDICINAL MANUFACTURE THEREOF | JIKAI BIOSCIENCES INC (CN) | 2017-05-31 | — | — | EP | disclosed |
| US-9090594-B2 | PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2015-07-28 | — | — | US | disclosed |
| EP-2743271-A1 | PIM KINASE INHIBITOR AND PREPARATION METHOD AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences Inc. (CN) | 2014-06-18 | — | — | EP | disclosed |
| US-20140162999-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. (CN) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162999-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | CHRM2 4194/4885CHRM1 3107/4885CHRM3 3950/4885 |
| US-20240173439-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | AFF1, AFF2, AFF4 | CHRM2 112/4885CHRM1 41/4885CHRM3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.